We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+21.59%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$852M
AUM Growth
+$102M
Cap. Flow
+$2.45M
Cap. Flow %
0.29%
Top 10 Hldgs %
62.79%
Holding
32
New
4
Increased
14
Reduced
5
Closed
9

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$36.9M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$27M
3
BIIB icon
Biogen
BIIB
+$23.8M
4
VOR icon
Vor Biopharma
VOR
+$23.4M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$22.8M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$80.1M
2
AXSM icon
Axsome Therapeutics
AXSM
+$23.2M
3
ASND icon
Ascendis Pharma A/S
ASND
+$16.8M
4
ESPR
Esperion Therapeutics
ESPR
+$11.5M
5
MRUS
Merus
MRUS
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
26
DELISTED
Esperion Therapeutics
ESPR
– –
-1,719,831
Closed -$11.5M
MIST icon
27
Milestone Pharmaceuticals
MIST
$146M
– –
-634,211
Closed -$5.83M
MRUS
28
DELISTED
Merus
MRUS
– –
-564,214
Closed -$11.3M
TGTX icon
29
TG Therapeutics
TGTX
$7.46B
– –
-1,505,479
Closed -$8.91M
GTHX
30
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-884,574
Closed -$11M
OYST
31
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
– –
-1,648,316
Closed -$9.26M
GBT
32
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-1,175,879
Closed -$80.1M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SMFG
Sumitomo Mitsui Financial Group Tokyo, Japan $4.94B AUM 1.39% 1-Year Est. Return

Paradigm Biocapital Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Paradigm Biocapital Advisors held 32 positions worth $852M, up 14% from $750M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Paradigm Biocapital Advisors's Q4 2022 filing shows 4 new, 14 increased, 5 reduced and 9 closed positions. Its largest new stake was Seagen Inc. Common Stock: 286,288 shares worth $36.8M. The largest sale was Global Blood Therapeutics, Inc., an estimated $80.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

  • Paradigm Biocapital Advisors's largest Q4 2022 buy was Seagen Inc. Common Stock: 286,288 shares worth $36.8M.
  • Paradigm Biocapital Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $27M increase.
  • Paradigm Biocapital Advisors's biggest Q4 2022 reduction was Ascendis Pharma A/S, cutting an estimated $16.8M.
  • Paradigm Biocapital Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $80.1M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 63% of its $852M portfolio in Q4 2022.
  • Paradigm Biocapital Advisors opened 4 new positions and closed 9 in Q4 2022.
  • Paradigm Biocapital Advisors's portfolio value rose 14% quarter-over-quarter to $852M.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.